• Subscribe
  • Magazine
  • Videos
  • Advertise
  • About Us
  • Smart Water Summit
  • Wastewater Summit
    • Recent Quotes
    My Watchlist
    Indicators
    WaterWorld Market Index
    Markets
    Stocks
    ETFs
    Tools
    Overview
    News
    Currencies
    International
    Treasuries

    Incannex Healthcare Inc. - Common Stock (NQ: IXHL )

    2.581 +0.001 (+0.03%)
    Streaming Delayed Price Updated: 2:37 PM EST, Nov 4, 2024 Add to My Watchlist
    Quote
    Overview Detailed Quote Charting Historical Prices
    News
    All News News Headlines Press Releases
    Research
    Quarterly Reports Insider Filings Other Filings

    All News about Incannex Healthcare Inc. - Common Stock

    < Previous 1 2 3 4 5 6 7 8 Next >
    12 Health Care Stocks Moving In Friday's Pre-Market Session
    Via Benzinga
    12 Health Care Stocks Moving In Thursday's Intraday Session
    Via Benzinga
    Incannex Approved For Bioavailability Clinical Trial For Dronabinol-Based Drug For Treatment Of Obstructive Sleep Apnea
    Incannex Healthcare Limited (NASDAQ: IXHL) (ASX:IHL) has received approval from Bellberry Human Research Ethics Committee to commence a bioavailability/bioequivalence (‘BA/BE’) clinical trial on... 
    Via Benzinga
    12 Health Care Stocks Moving In Thursday's Pre-Market Session
    Via Benzinga
    Why Incannex Healthcare Shares Are Gaining Today
    Via Benzinga
    Upward Trend In Largest Psychedelic Compound-Based R&D Stocks Continues
    Our Psychedelic Drug Stocks Index, which consists of the 6 largest psychedelic compound-based research & development companies, was up 3.4% this week, up 7.1% in June, up 6.3% in May, and is now up... 
    Via Talk Markets
    Incannex appoints principal investigators for pivotal IHL-42X trial
    Incannex appoints principal investigators for pivotal IHL-42X trial 
    Via News Direct
    Exposures Product Safety
    Incannex appoints principal investigators for pivotal IHL-42X trial
    Incannex Healthcare Ltd (ASX:IHL, NASDAQ:IXHL) CEO Joel Latham tells Proactive the company has appointed two highly experienced lead principal investigators for its Phase 2/3 clinical trial of IHL-42X,... 
    Via TheNewswire.com
    Exposures Product Safety
    Upward Trend In Major Psychedelic Compound-Based Research & Development Stocks Continue
    There are 6 constituents in our munKNEE Psychedelic Drug Stocks Index and 5 of them advanced this week and are now all up MTD. 
    Via Talk Markets
    Major Psychedelic Compound-Based Research & Development Stocks: June Update
    Psychedelic Drug Stocks Index has been revamped with the removal of Cybin (CYBN) which has dropped below $100M in market capitalization leaving 6 constituents in the Index 
    Via Talk Markets
    Psyched: Millions From Institutional Investor And Fed Funding For Research, M&As, Women Veterans And More
    Major Investor Commits $30 Million To Psychedelics Funding 
    Via Benzinga
    Why A National Cannabis Organization Sacked Half Its Staff, CEO Turnovers And More Exec Changes
    NCIA Sacks Half Of Its Team To Increase Financial Strength 
    Via Benzinga
    May Summary Of Largest Psychedelic Compound-Based Drug Stock Performances
    Only two of the seven largest psychedelic compound-based drug stocks tracked, advanced in May. 
    Via Talk Markets
    Incannex welcomes world-leading psychedelics experts to advisory board
    Incannex Healthcare Ltd (ASX:IHL, NASDAQ:IXHL) director Peter Widdows tells Proactive the company has appointed three world-renowned psychedelic therapy and science experts to its Clarion Clinics Group... 
    Via TheNewswire.com
    Incannex welcomes world-leading psychedelics experts to advisory board
    Incannex welcomes world-leading psychedelics experts to advisory board 
    Via News Direct
    Psyched: New Psilocybin Forms, LSD Anxiety Study, UK's Parliamentary Debate And More
    Biotech Company Discovers What May Be The First New Compounds Of Psilocybin In History NY-based biotech platform Terran Biosciences announced the publication of an international PCT patent application... 
    Via Benzinga
    Psychedelic Therapies Soon Available In Australia Via Incannex Healthcare And Subsidiary
    Biotech giant Incannex Healthcare Ltd (NASDAQ: IXHL) shared a business presentation of its newly formed psychedelic-assisted therapies subsidiary company, Psychennex Pty Ltd. 
    Via Benzinga
    Psyched: Psychedelics Reimbursement, Amanita Muscaria Boom, $53M Material Breach Lawsuit & More
    EXCLUSIVE: AMA Moves Toward Psychedelic Therapy Reimbursement, Filing A Gap In Regulations 
    Via Benzinga
    Incannex Stock Trading Higher On Entering A Lease For First Psychedelic-Assisted Psychotherapy Clinic
    Incannex Healthcare Ltd (NASDAQ: IXHL) (ASX:IHL) announced that its subsidiary company, Clarion Clinics Group Pty Ltd, has entered a lease for riverfront premises in Abbottsford, Melbourne. 
    Via Benzinga
    Incannex readying for Phase 2 clinical trial of anti-inflammatory drug IHL-675A
    Incannex Healthcare Ltd (ASX:IHL, NASDAQ:IXHL) chief medical officer Dr Mark Bleakley speaks with Proactive soon after announcing final results for a Phase 1 clinical trial to assess pharmacokinetics... 
    Via TheNewswire.com
    Incannex readying for Phase 2 clinical trial of anti-inflammatory drug IHL-675A
    Incannex readying for Phase 2 clinical trial of anti-inflammatory drug IHL-675A 
    Via News Direct
    Psyched: Oregon And Colorado Regulations, MindMed CEO Discusses LSD Therapy, Mia Khalifa Enters Market & More
    Oregon Pioneers Legal Psilocybin Therapy, But This Type Of License Has Yet To Be Issued 
    Via Benzinga
    April Psychedelic Drug Stocks Recap: The Ups And Downs
    Via Talk Markets
    New Clinical MDMA And Psilocybin Batches Head To Flourishing Psychedelics Market
    Psychedelics developer PharmAla Biotech continues to provide its Good Manufacturing Practices (GMP)-compliant psychedelics to Australian-based businesses developing clinical trials and, soon, actual... 
    Via Benzinga
    Largest Psychedelic Stocks -3.4% In March
    The munKNEE Psychedelic Drug Stocks Index was down 3.4% in March but is still +1.2% YTD. The best news is the continuing high price targets being set by analysts. 
    Via Talk Markets
    Cannabis Category Performances Ranged From +8.6% To -7.0% This Week
    The 5 categories in the cannabis sector perform quite differently from each other and this week was a prime example. 
    Via Talk Markets
    Psyched: 22 States With Reform Bills, Ketamine Therapy Services Today, Oscars On Shrooms & More
    Psychedelics Reform Update: 22 States Where Proposals Are Being Discussed & Local Moves Considered 
    Via Benzinga
    Incannex Healthcare Prepares To Launch Psychedelics Clinics Via New Subsidiary
    Australia-based biopharma giant Incannex Healthcare Ltd. (NASDAQ: IXHL) has plans to commercialize its psychedelic-assisted psychotherapy business through a new subsidiary venture under the leadership... 
    Via Benzinga
    Psychedelic Trials Update: Treating Meth Addiction, Fibromyalgia & General Anxiety Disorder
    Three companies have provided updates on their efforts to assess different psychedelics for treating a widely varied set of conditions. 
    Via Benzinga
    Why American Public Education Shares Are Trading Lower By Around 49%? Here Are Other Stocks Moving In Wednesday's Mid-Day Session
    Gainers ThermoGenesis Holdings, Inc. (NASDAQ: THMO) shares jumped 80% to $3.7820 after the company announced the roll out of ReadyStart cGMP Suites for early-stage cell and gene-therapy companies. 
    Via Benzinga
    < Previous 1 2 3 4 5 6 7 8 Next >
    Data & News supplied by www.cloudquote.io
    Stock quotes supplied by Barchart
    Quotes delayed at least 20 minutes.
    By accessing this page, you agree to the following
    Privacy Policy and Terms and Conditions.